Search for content, post, videos

Category

Clinical Trials

Martin-Bonde-vaccibody
0 COMMENT
98 Views
Vaccibody moves forward with clinical study

Norwegian company Vaccibody is moving forward with the first vaccination of a patient with the human papillomavirus, HPV-virus, in a phase IIa study using the company´s immunotherapy platform. The primary objectives of the phase IIa study are to assess T cell mediated immune responses in the peripheral blood and to…

umecrine
0 COMMENT
130 Views
First patient included in Umecrine’s study

Karolinska Development’s portfolio company Umecrine Cognition announces the inclusion of the first patient in a clinical Phase Ib/IIa study of GR3027, which is in development as a potential new treatment for Hepatic Encephalopathy. The objectives of the study (protocol UCAB-CT-02) are to evaluate the safety and pharmacokinetics of steady-state dosing…

medivir-research
0 COMMENT
88 Views
Positive data from Medivir

Medivir announces the completion of the phase II clinical study of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in patients with early stage CTCL. The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to receive either 0.5% remetinostat gel BID, 1% remetinostat…

per-norlen-foto-jenny-leyman
0 COMMENT
103 Views
Alligator completes Phase I trial

Biotech company Alligator Biosciences has finished its first Phase I clinical trial with the immuno-oncology antibody ADC-1013. CDMO Cobra Biologics has manufactured the antibody as part of the company’s cell line development programme for Alligator. Cobra has developed the cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using their maxXpress…

ascendis_pharma
0 COMMENT
106 Views
Ascendis Pharma presents new data

Ascendis Pharma has announced data supporting its product pipeline presented at ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida. “We are delighted to show the breadth of our growing pipeline at this year’s ENDO conference, including three potentially differentiated treatments for rare endocrine diseases,” said Jonathan…

Johan_Haggblad
0 COMMENT
148 Views
Positive results from Pharmalink trial

Pharmalink announces that positive results and analyses from the completed Phase 2b trial of its oral drug candidate Nefecon in primary IgA nephropathy (IgAN) patients have been published online in The Lancet. This is the first time the full results from this trial have been published in this format. In…

acarix-ceo
0 COMMENT
86 Views
New results from Acarix study

Acarix has announced the results from a new multi-center trial of its handheld CADScor System for non-invasive, non-radiation acoustic detection of Coronary Artery Disease. The results were presented at the American College of Cardiology 2017 Annual Scientific Meeting held in Washington on 17-19 March 2017 and showed that the handheld…

henrik-wnt
0 COMMENT
123 Views
Positive results from Wnt Research

WntResearch announces that the company has obtained positive results from the analyses of patient tumour tissue samples before and after treatment in a Phase 1b study with Foxy-5 – a drug candidate intended to inhibit tumours from spreading in cancer patients. Based on the obtained results, the company has defined…

nordic nanovector
0 COMMENT
75 Views
First patient dosed in Nordic Nanovector study

Nordic Nanovector announces that the first patient has been dosed in its Phase 1 study evaluating Betalutin (177Lu-satetraxetan-lilotomab), a novel CD37 targeting antibody-radionuclide conjugate, in patients with relapsed diffuse large B-cell lymphoma (DLBCL) – the “LYMRIT 37-05” trial. “We are excited to begin this study to evaluate Betalutin in patients…

oncology-antibody-astrazeneca
0 COMMENT
74 Views
New data from AZ’s Phase III solo-2 study

AstraZeneca presented results from the Phase III SOLO-2 trial demonstrating a significant improvement in progression-free survival in germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza tablets compared with placebo in the maintenance setting. PFS as measured by Blinded Independent Central Review (BICR)evaluation, a pre-specified analysis supporting the primary…

immunovia
0 COMMENT
36 Views
Immunovia’s retrospective autoimmune disease study has been finalized

Immunovia announces that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s IDEA Centre has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray blood-based biomarker signatures in differentiating SLE from three other…

leo-pharma-research
0 COMMENT
28 Views
LEO Pharma announces positive clinical trial results

LEO Pharma announces positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. Tralokinumab is an investigational monoclonal antibody that specifically targets the cytokine IL-13,which plays an important role in…

alk-produktion
0 COMMENT
72 Views
Data from ALK results in significant change to the GINA asthma management strategy

ALK has announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management and Prevention. This global strategy is a practical resource developed to guide healthcare professionals and policy makers, and represents the latest…